please review product information before … · 2019-05-02 · adapted from murphy k et al....
TRANSCRIPT
Entry inhibitors work outside the cell. They prevent HIV from entering the CD4 cell by blocking binding or fusion of HIV with the CD4 cell membrane. If HIV cannot enter the CD4 cell it is unable to replicate.
Fusion and Entry inhibitors
Non-nucleoside reverse transcriptase
inhibitors
Non-nucleoside reverse transcriptase inhibitors bind to reverse transcriptase and inhibit the enzyme, stopping HIV replication by preventing formation of HIV DNA. These drugs act in a completely different way to nucleoside / nucleotide analogues.
Nucleoside/Nucleotide analogues
Nucleoside / nucleotide analogues act as false substrates for reverse transcriptase, causing chain termination. The resulting DNA is incomplete and prevents HIV replication.
Integrase inhibitors
Integrase inhibitors block the integration of HIV and cell DNA. This process prevents HIV replication.
Protease inhibitors
Protease inhibitors work at the last stage of the HIV replication cycle. They prevent HIV from being successfully assembled and released from the infected CD4 cell.
TARGETING HIV REPLICATION1,2
Stages of HIV replication
1. HIV enters a CD4 cell.
2. HIV is a retrovirus, meaning that its genetic information is stored on single-stranded RNA instead of the double-stranded DNA found in most organisms.
3. HIV DNA enters the nucleus of the CD4 cell and inserts itself into the cell’s DNA. HIV DNA then instructs the cell to make many copies of the original virus.
4. New virus particles are assembled and leave the cell, ready to infect other CD4 cells.
Antiretroviral Agents for HIV
Antiretroviral AgentsAdult Dosage CardAUGUST 2018
PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Product information is available from the relevant manufacturer.
Viramune®, Aptivus® are registered trademarks of Boehringer Ingelheim Pty Ltd. Stocrin®, Isentress® are registered trademarks of Merck Sharp & Dohme.
Intelence®, Edurant®, Prezista®, Prezcobix® are registered trademarks of Janssen-Cilag Pty Ltd.
Reyataz®, Evotaz™ are registered trademarks of Bristol-Myers Squibb Australia Pty Ltd.
Retrovir, 3TC, Combivir, Ziagen, Kivexa, Trizivir, Telzir, Celsentri, Tivicay, Triumeq, Juluca Trade marks are owned by or licensed to the ViiV Healthcare group of companies.
Viread®, Truvada®, Descovy®, Atripla®, Eviplera®, Odefsey®, Stribild®, Genvoya®, Biktarvy® are registered trademarks of Gilead Sciences Pty Ltd.
Kaletra®, Norvir® are registered trademarks of AbbVie Pty Ltd. Fuzeon®, Invirase® are registered trademarks of F Hoffmann-La Roche AG.
For information on ViiV Healthcare products or to report an adverse event involving a ViiV Healthcare product,
please contact GSK Medical Information on 1800 499 226 or e-mail [email protected]
ViiV Healthcare Pty Ltd. Level 3, 436 Johnston St, Abbotsford VIC 3067, ACN 138 687 448.
© 2018 ViiV Healthcare group of companies or its licensor. Date of preparation: August 2018. AUS/HIV/0117/18
Reference: 1. Adapted from Murphy K et al. Janeway’s Immunobiology, 8th Edition Garland Science, 2012 Chapter 13.
2. Adapted from Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Downloaded from https://aidsinfo.nih.gov/guidelines
The Antiretroviral Agents Adult Dosage Card was originally developed by Boehringer Ingelheim and we acknowledge their contribution to HIV management.
PROT
EASE
INHI
BITO
RS (P
I)
SINGL
E PILL
REGIM
ENS
Juluca(dolutegravir/rilpivirine)
1 x 50 mg / 25 mg tablet once daily
Triumeq(dolutegravir/abacavir/lamivudine)
1 x 50 mg / 600 mg / 300 mg tablet once daily
Biktarvy®(tenofovir alafenamide/emtricitabine/bictegravir)
1 x 25 mg / 200 mg / 50 mg tablet once daily
Odefsey®(tenofovir alafenamide/emtricitabine/rilpivirine)
1 x 25 mg / 200 mg / 25 mg tablet once daily
Genvoya®(tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat)
1 x 10 mg / 200 mg / 150 mg / 150 mg tablet once daily
Stribild®(tenofovir disoproxil fumarate/ emtricitabine/elvitegravir/cobicistat)
1 x 300 mg / 200 mg / 150 mg / 150 mg tablet once daily
Eviplera®(tenofovir disoproxil fumarate/emtricitabine/rilpivirine)
1 x 300 mg / 200 mg / 25 mg tablet once daily
Atripla®(tenofovir disoproxil fumarate/ emtricitabine/efavirenz)
1 x 300 mg / 200 mg / 600 mg tablet once daily
® Registered Trademark TM Trademark † Please refer to product information before prescribing as dosing may change with some combinations or patient types *Or as directed by physician
NON
-NUC
LEOS
IDE
REVE
RSE
TRAN
SCRI
PTAS
E IN
HIBI
TORS
(NN
RTI)
Viramune®
(nevirapine)1 x 200 mg tablet 2 times a day 1 x 400 mg tablet once daily
or
Stocrin®(efavirenz)
1 x 600 mg tablet once daily
Intelence®(etravirine)
1 x 200 mg tablet 2 times a day
Edurant®(rilpivirine)
1 x 25 mg tablet once daily
100 mg / 25 mg also available (not shown)
INTE
GRAS
E INH
IBITO
RS
Isentress®(raltegravir)
1 x 400 mg tablet 2 times a day 2 x 600 mg tablets once dailyor
Tivicay(dolutegravir)
1 x 50 mg tablet once daily
CLASS/DRUG USUAL ADULT DAILY DOSING† *
(products depicted in this column are not the actual size) ACTUAL SIZE CLASS/DRUG USUAL ADULT DAILY DOSING† *
(products depicted in this column are not the actual size) ACTUAL SIZE CLASS/DRUG USUAL ADULT DAILY DOSING† *
(products depicted in this column are not the actual size) ACTUAL SIZEN
UCL
EOSI
DE
/ NU
CLEO
TID
E RE
VERS
E TR
AN
SCRI
PTA
SE IN
HIB
ITO
RS (N
RTI /
NtR
TI)
ENTR
Y IN
HIBI
TORS
Fuzeon®(enfuvirtide) also known as T-20
1 x 90 mg vial 2 times a day
Celsentri(maraviroc)
1 x 150 mg tab or 1 x 300 mg tab or 2 x 300 mg tabs2 times a day 2 times a day 2 times a day
Fuzeon is available as powder for reconstitution (90 mg vial) for
subcutaneous injection
Crixivan®(indinavir)
2 x 400 mg capsules 3 times a day
Invirase®(saquinavir)
2 x 500 mg tablets 2 times a day
Kaletra®(lopinavir/ritonavir)
2 x 200 mg / 50 mg tablets 2 times a day 4 x 200 mg / 50 mg tablets once dailyor
Telzir(fosamprenavir calcium)
1 x 700 mg tablet 2 times a day 2 x 700 mg tablets once dailyor
Reyataz®(atazanavir)
1 x 300 mg capsule once daily 2 x 200 mg capsules once dailyor
Evotaz™(atazanavir/cobicistat)
1 x 300 mg / 150 mg tablet once daily
Aptivus®(tipranavir)
2 x 250 mg capsules 2 times a day
Prezista®(darunavir)
1 x 800 mg tablet once daily 1 x 600 mg tablet 2 times a dayor
Prezcobix®(darunavir/cobicistat)
1 x 800 mg / 150 mg tablet once daily
Norvir®(ritonavir)
6 x 100 mg tablets 2 times a day
Retrovir(zidovudine) also known as AZT
2 x 100 mg capsules 3 times a day 1 x 250 mg capsule 2 times a dayor
3TC(lamivudine)
1 x 150 mg tablet 2 times a day 1 x 300 mg tablet once dailyor
Combivir(lamivudine/zidovudine)
1 x 150 mg / 300 mg tablet 2 times a day
Ziagen(abacavir)
1 x 300 mg tablet 2 times a day 2 x 300 mg tablets once dailyor
Kivexa(abacavir/lamivudine)
1 x 600 mg / 300 mg tablet once daily
Trizivir(abacavir/lamivudine/zidovudine)
1 x 300 mg / 150 mg / 300 mg tablet 2 times a day
Emtriva®(emtricitabine) also known as FTC
1 x 200 mg capsule once daily
Viread®(tenofovir disoproxil fumarate)
1 x 300 mg tablet once daily
Truvada®(tenofovir disoproxil fumarate/emtricitabine)
1 x 300 mg / 200 mg tablet once daily
Descovy®(tenofovir alafenamide/emtricitabine)
1 x 25 mg / 200 mg tablet once daily 1 x 10 mg / 200 mg tablet once dailyor Antiretroviral Agents
Adult Dosage CardAUGUST 2018